Volunteers - U.S. Only
Thank you for your interest in the CARE-MSSM I and II global multiple sclerosis clinical research studies. Both studies are enrolling patients and are designed to determine the safety and the effectiveness of the investigational drug alemtuzumab as compared to the FDA-approved therapy Rebif® (which has a scientific or generic name of interferon beta-1a), in patients with relapsing-remitting multiple sclerosis (sometimes called RRMS).
.............................................................................
0 comments:
Post a Comment